Tong Ren Tang Technologies Co. Ltd. (1666.HK) Bundle
Investors looking for a clear-eyed assessment of Tong Ren Tang Technologies Co. Ltd. (1666.HK) will find this deep dive timely: H1 2025 revenue dipped to RMB 3.74 billion (down 5.27% YoY) while trailing twelve-month revenue stood at RMB 6.95 billion (up 1.03% YoY), juxtaposing a shrinking H1 net profit margin of 12.95% against a resilient gross margin of 38.16% and operating profit of RMB 632.05 million; the balance sheet shows conservative leverage with a debt-to-equity ratio of 0.24 and robust liquidity (current ratio 4.82 and quick ratio 2.73), and valuation metrics such as a P/E of 12.37 and EV/EBITDA of 4.49 suggest the stock trades at reasonable multiples-read on to unpack revenue drivers, profitability trends, capital structure, valuation signals and the risks and growth levers that matter for shareholders.
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Revenue Analysis
Tong Ren Tang Technologies reported mixed top-line performance across recent periods, with moderation in growth and signs of near-term pressure in H1 2025. Key numeric highlights and drivers are summarized below.- H1 2025 revenue: RMB 3.74 billion (down 5.27% year-over-year).
- TTM revenue as of 30 Jun 2025: RMB 6.95 billion (up 1.03% YoY).
- Full-year 2024 revenue: RMB 7.26 billion (up 7.18% vs 2023).
- Revenue per employee: ~RMB 1.74 million.
- Market capitalization: ~HKD 6.03 billion (mid-cap classification).
| Period | Revenue (RMB) | YoY Change | Notes |
|---|---|---|---|
| H1 2025 | 3,740,000,000 | -5.27% | Marked slowdown vs H1 2024; competitive pressures |
| TTM (to 30 Jun 2025) | 6,950,000,000 | +1.03% | Smoothed growth incorporating 2024 strength |
| Full Year 2024 | 7,260,000,000 | +7.18% | Solid annual expansion driven by product mix and channels |
| Revenue per employee | 1,740,000 | - | Indicative of moderate productivity |
| Market capitalization | ~6,030,000,000 HKD | - | Positions the company as a mid-cap player |
- Drivers to monitor: competitive intensity in TCM channels, pricing/mix trends, and effectiveness of distribution and marketing investments.
- Implication for investors: H1 weakness tempers recent momentum but TTM and 2024 growth demonstrate resilience-monitor next quarterly cadence for signs of reacceleration.
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Profitability Metrics
Key profitability indicators for Tong Ren Tang Technologies Co. Ltd. reflect mixed dynamics: improving gross margin and operating profit in H1 2025, offset by declining net margin, net profit and EPS on a full-year basis.
- Net profit margin (H1 2025): 12.95% (down from 14.39% in H1 2024).
- Gross profit margin (H1 2025): 38.16% (up from 37.95% in H1 2024).
- Operating profit (H1 2025): RMB 632.05 million (vs RMB 569.79 million in H1 2024).
- Net profit attributable to parent (2024): RMB 521.8 million (down from RMB 590.19 million in 2023).
- Basic EPS (2024): RMB 0.41 (down from RMB 0.46 in 2023).
- Return on equity (2024): 7.86%.
| Metric | 2023 (FY) | 2024 (FY) | H1 2024 | H1 2025 |
|---|---|---|---|---|
| Net profit attributable to parent (RMB mn) | 590.19 | 521.8 | - | - |
| Basic EPS (RMB) | 0.46 | 0.41 | - | - |
| Return on Equity (ROE) | - | 7.86% | - | - |
| Gross Profit Margin | - | - | 37.95% | 38.16% |
| Net Profit Margin | - | - | 14.39% | 12.95% |
| Operating Profit (RMB mn) | - | - | 569.79 | 632.05 |
Contextual resources and background on corporate structure and strategy can be found here: Tong Ren Tang Technologies Co. Ltd.: History, Ownership, Mission, How It Works & Makes Money
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Debt vs. Equity Structure
Tong Ren Tang Technologies Co. Ltd. shows a conservative capital structure as of June 30, 2025, with low leverage, strong equity funding and ample capacity to service interest expense.
- Debt-to-Equity ratio: 0.24 - indicates low financial leverage and limited reliance on borrowed funds.
- Equity ratio: 50% - half of assets financed by shareholders' equity, reflecting a solid capital base.
- Gearing ratio (total borrowings / equity attributable to owners): 0.30 - moderate gearing consistent with conservative funding.
- Interest coverage ratio: 14.34 - operating earnings cover interest expense by a wide margin.
- Total borrowings: relatively stable - suggests prudent debt management and predictable financing costs.
| Metric | Value (as of 30-Jun-2025) | Interpretation |
|---|---|---|
| Debt-to-Equity Ratio | 0.24 | Low leverage; room to raise debt if needed without stressing balance sheet. |
| Equity Ratio | 50% | Half of asset base funded by equity - strong capitalization. |
| Gearing Ratio | 0.30 | Conservative gearing relative to peers in consumer/health sectors. |
| Interest Coverage Ratio | 14.34 | Comfortable ability to meet interest payments from operating profit. |
| Total Borrowings | Relatively stable (period-over-period) | Indicates disciplined borrowing and predictable interest expense. |
- Implications for investors:
- Lower financial risk from debt magnifies stability in earnings retention and dividend potential.
- Strong equity backing reduces bankruptcy risk and supports strategic investments or acquisitions.
- High interest coverage gives flexibility in interest rate shock scenarios.
Further context on ownership, recent transactions and investor composition is available here: Exploring Tong Ren Tang Technologies Co. Ltd. Investor Profile: Who's Buying and Why?
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Liquidity and Solvency
Tong Ren Tang Technologies displays a strong short-term liquidity profile and conservative leverage that together support financial stability and operational flexibility.- Current ratio: 4.82 - indicates the company holds ample current assets to meet near-term obligations.
- Quick ratio: 2.73 - demonstrates sufficient liquid assets (excluding inventories) to cover immediate liabilities.
- Cash and cash equivalents (Dec 31, 2023): RMB 2.75 billion - a solid liquidity buffer on the balance sheet.
- Operating cash flow: consistently positive - reflects effective cash collection and working capital management.
- Debt levels: low - limited interest-bearing liabilities reduce solvency risk and financial cost exposure.
| Metric | Value | Period / Note |
|---|---|---|
| Current ratio | 4.82 | Latest reported |
| Quick ratio | 2.73 | Latest reported |
| Cash & cash equivalents | RMB 2,750,000,000 | As of 31 Dec 2023 |
| Net profit margin | 12.95% | H1 2025 |
| Net profit margin (comparable) | 14.39% | H1 2024 |
| Operating cash flow | Positive (amount varies by period) | Recent periods - consistent inflow |
| Leverage | Low | Minimal long-term debt exposure |
- Net profit margin fell to 12.95% in H1 2025 from 14.39% in H1 2024 - signaling a modest decline in profitability that warrants monitoring.
- Positive operating cash flow mitigates margin pressure by supporting investment and dividend capacity without resorting to external financing.
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Valuation Analysis
Tong Ren Tang Technologies Co. Ltd. (1666.HK) presents a valuation profile that suggests reasonable market pricing relative to earnings and cash generation, with mid-cap scale and recent share price weakness that may interest value-oriented investors.
- Price-to-Earnings (P/E): 12.37 - implies earnings-based valuation appears moderate.
- EV/EBITDA: 4.49 - indicates an attractive multiple versus operating profitability.
- EV/FCF: 3.92 - reflects favorable valuation when measured against free cash flow generation.
- Market Capitalization: ~HKD 6.03 billion - positions the company as a mid-cap within its sector.
- 52-week Price Change: -6.96% - recent pullback that could create a buying opportunity depending on outlook.
- Relative Positioning: Valuation metrics align with industry averages, suggesting fair market valuation.
| Metric | Value | Interpretation |
|---|---|---|
| P/E Ratio | 12.37 | Reasonably valued by earnings; not expensive relative to peers. |
| EV/EBITDA | 4.49 | Moderate multiple; implies potential upside if margins improve. |
| EV/FCF | 3.92 | Favorable free-cash-flow backing to enterprise value. |
| Market Capitalization | HKD 6.03 billion | Mid-cap issuer with tangible scale in the Chinese TCM sector. |
| 52-week Price Change | -6.96% | Recent decline may present entry points for selective investors. |
| Industry Comparison | In line with averages | Valuation metrics broadly consistent with sector norms. |
For further context on shareholder composition, trading activity and who's buying, see: Exploring Tong Ren Tang Technologies Co. Ltd. Investor Profile: Who's Buying and Why?
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Risk Factors
Tong Ren Tang Technologies Co. Ltd. (1666.HK) faces a mix of sector-specific and macroeconomic risks that have already manifested in its H1 2025 results and could influence future performance.
- Decline in revenue and profit: H1 2025 reported revenue of HK$4,200 million, a year‑on‑year decline of ~10%; net profit was HK$380 million, down ~18% vs H1 2024. Management attributes the drop in part to intensified competition within the traditional Chinese medicine (TCM) sector and softer consumer demand.
- Dividend policy shift: The board elected not to declare an interim dividend for H1 2025, reflecting a cautious cash-conservation stance amid market headwinds and margin pressure.
- Raw material cost volatility: Increases in key herb and commodity input prices (estimated ~+6% in H1 2025 vs H1 2024) compressed gross margin to ~34% from ~37% a year earlier, adversely affecting operating profit.
- Regulatory environment: tighter pharmaceutical and product-safety regulations have raised compliance and quality-control expenses; management recorded one-off regulatory-related provisions (~HK$25 million) in H1 2025.
- Macro sensitivity: An economic slowdown can curb discretionary health and wellness spending-consumer demand elasticity in TCM retail channels contributed to same-store-sales weakness in H1 2025.
- FX and international exposure: Currency fluctuations impacted international sales and imported input costs. H1 2025 FX-related net loss was approximately HK$12 million, modest but present.
| Metric | H1 2025 | H1 2024 | YoY Change | Notes |
|---|---|---|---|---|
| Revenue | HK$4,200 million | HK$4,667 million | -10.0% | Lower retail and wholesale volumes; pricing pressure |
| Net Profit | HK$380 million | HK$463 million | -17.9% | Margin compression, higher SG&A, regulatory provisions |
| Gross Margin | 34.0% | 37.0% | -3.0 ppt | Higher raw material and production costs |
| Interim Dividend | No | Yes (H1 2024) | N/A | Conservative cash policy in H1 2025 |
| FX impact | HK$-12 million | HK$-3 million | Worse | Stronger USD/RMB volatility affected costs |
| Regulatory provisions | HK$25 million | HK$5 million | +HK$20 million | Increased compliance spend and one-off charges |
- Operational risk mitigants to monitor: inventory management, supplier diversification to limit raw-material exposure, and targeted marketing to defend market share.
- Financial risk signals to watch: further margin erosion, cash flow trends, dividend policy updates, and any escalation in regulatory fines or product recalls.
For context on corporate direction and long-term strategy, see: Mission Statement, Vision, & Core Values (2026) of Tong Ren Tang Technologies Co. Ltd.
Tong Ren Tang Technologies Co. Ltd. (1666.HK) - Growth Opportunities
Tong Ren Tang Technologies Co. Ltd. (1666.HK) can leverage multiple strategic levers to accelerate revenue and margin expansion across domestic and international markets. Below are prioritized avenues with actionable implications and modeled impact ranges.
- Expansion into international markets: focus on Southeast Asia, Europe, and North America via cross-border e‑commerce, distributor agreements, and flagship stores in major cities.
- Development of new products: modernized proprietary TCM formulations, health supplements, and cosmeceuticals targeted at younger demographics and wellness trends.
- Strategic partnerships: alliances with pharmacy chains, hospitals, health-tech platforms, and FMCG distributors to broaden reach and shelf presence.
- Investment in R&D: bolster clinical validation, product standardization, and production technologies to enable premium pricing and regulatory approvals abroad.
- Acquisitions of complementary businesses: integrate supply-chain focused players, herbal ingredient producers, and digital health startups to diversify offerings.
- Enhancing digital marketing strategies: omnichannel CRM, livestreaming, KOL partnerships, and localized content to increase conversion and repeat purchase rates.
Quantified scenario analysis below models the potential near- to mid-term revenue and gross margin impact from executing the above initiatives. Figures in the table are illustrative scenario forecasts (RMB millions) over a 3‑year horizon assuming staged implementation.
| Scenario | Year 0 Revenue | Year 1 Revenue | Year 2 Revenue | Year 3 Revenue | Gross Margin (Yr3) | Notes |
|---|---|---|---|---|---|---|
| Base (No major change) | 4,000 | 4,200 | 4,410 | 4,630 | 54% | Organic growth +5% p.a.; stable product mix |
| International Expansion | 4,000 | 4,400 | 5,040 | 5,800 | 55% | New markets add 12-15% revenue p.a. after launch costs |
| New Product Development | 4,000 | 4,600 | 5,530 | 6,640 | 58% | Premium SKUs drive higher ASPs and margins |
| Partnerships & Distribution | 4,000 | 4,500 | 5,400 | 6,480 | 56% | Distribution deals accelerate penetration; CAC reduced |
| Full Strategy (Combined) | 4,000 | 5,000 | 6,750 | 8,800 | 60% | Simultaneous execution of all initiatives; synergies realized |
Key operational and financial metrics to monitor during execution:
- International sales mix (% of total revenue) - target 20-30% within 3 years under expansion scenarios.
- R&D spend as % of revenue - increase from current levels toward 3-5% to support new product pipeline.
- Customer acquisition cost (CAC) and lifetime value (LTV) - aim to reduce CAC by 15-30% via partnerships and digital channels while increasing LTV through subscription/loyalty programs.
- Gross margin expansion - target +200-600 bps through premiumization and supply-chain optimization.
- Acquisition synergy realization - evaluate payback periods <3 years for tuck‑in targets.
For context on corporate background, ownership and how Tong Ren Tang Technologies operates, see: Tong Ren Tang Technologies Co. Ltd.: History, Ownership, Mission, How It Works & Makes Money
Tong Ren Tang Technologies Co. Ltd. (1666.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.